Femasys (FEMY) Competitors

Femasys (NASDAQ:FEMY) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.

Does the MarketBeat Community believe in FEMY or SGHT?

Femasys received 13 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 72.73% of users gave Femasys an outperform vote while only 31.15% of users gave Sight Sciences an outperform vote.

Company	Underperform	Outperform
Femasys	Outperform Votes 32 72.73%	Underperform Votes 12 27.27%
Sight Sciences	Outperform Votes 19 31.15%	Underperform Votes 42 68.85%

Does the media refer more to FEMY or SGHT?

In the previous week, Sight Sciences had 1 more articles in the media than Femasys. MarketBeat recorded 3 mentions for Sight Sciences and 2 mentions for Femasys. Sight Sciences' average media sentiment score of 0.51 beat Femasys' score of -0.04 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend FEMY or SGHT?

Femasys currently has a consensus target price of $10.00, suggesting a potential upside of 507.90%. Sight Sciences has a consensus target price of $4.68, suggesting a potential upside of 85.11%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts plainly believe Femasys is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sight Sciences	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Which has more risk and volatility, FEMY or SGHT?

Femasys has a beta of -2.81, meaning that its share price is 381% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.

Do institutionals & insiders believe in FEMY or SGHT?

65.3% of Femasys shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 12.3% of Femasys shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is FEMY or SGHT more profitable?

Sight Sciences has a net margin of -63.30% compared to Femasys' net margin of -1,435.77%. Sight Sciences' return on equity of -47.28% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-1,435.77%	-141.49%	-82.30%
Sight Sciences	-63.30%	-47.28%	-32.72%

Which has higher earnings and valuation, FEMY or SGHT?

Femasys has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.07M	35.21	-$14.25M	-$0.81	-2.03
Sight Sciences	$79.54M	1.61	-$55.55M	-$1.02	-2.48

Summary

Femasys beats Sight Sciences on 10 of the 18 factors compared between the two stocks.